Podcasts about Johns Hopkins

#689: Most people think forgetting a name means their brain is failing.  Dr. Majid Fotuhi, a neurologist who taught at Johns Hopkins and Harvard, sees thousands of patients convinced they have Alzheimer's – only to discover they're dealing with poor sleep or stress. Dr. Fotuhi joins us to break down the difference between cognitive decline, dementia and Alzheimer's disease. He explains why chronic stress physically shrinks your hippocampus — the thumb-sized memory center in your brain — and how twelve weeks of lifestyle changes reversed cognitive decline in 84 percent of his patients. We talk about the five hidden taxes draining your brain: sedentary lifestyle, poor sleep, junk food, chronic stress and mental laziness. Scrolling social media after work counts as mental laziness, even if your day job involves intense focus. Dr. Fotuhi offers a different framework: five pillars that compound over time. Exercise ranks first because it multiplies mitochondria in your brain cells, reduces inflammation and generates new neurons in your hippocampus. Walking 10,000 steps daily cuts Alzheimer's risk by 50 percent. Sleep comes second. Your brain rinses itself during deep sleep, flushing out amyloid — the core protein in Alzheimer's disease. One night of poor sleep increases amyloid in your brain. We cover nutrition (skip the junk food debate), mindset (heart rate variability breathing reduces Alzheimer's footprints) and brain training. Dr. Fotuhi memorizes 70 names in a single lecture and explains his technique for remembering credit card numbers using mental imagery. The conversation covers London taxi drivers who grew their hippocampus by memorizing 10,000 streets, why stress management beats supplements, and how Swedish students learning Arabic increased their brain volume in three months. Timestamps: Note: Timestamps will vary on individual listening devices based on dynamic advertising segments. The provided timestamps are approximate and may be several minutes off due to changing ad lengths. (00:00) Defining cognitive decline, dementia and Alzheimer's disease (05:19) Why cognitive issues don't always mean Alzheimer's (07:24) Thinking of your brain as an asset to manage (07:51) The five hidden taxes draining your brain (10:45) How poor sleep prevents brain rinsing and causes inflammation (14:20) Oral health and brain health connection (16:40) Brain plasticity and the Broca lobe (27:02) The five pillars of brain health (35:23) Cardiovascular fitness versus strength training for brain health (38:51) Sleep as the second pillar of brain health (48:05) When exercise beats sleep (51:33) Different types of intelligence beyond IQ tests (1:03:53) Reversing brain damage from decades of bad habits (1:10:25) Nutrition and avoiding junk food (1:25:09) Mindset and stress management as pillar four (1:33:35) Breathing exercises for stress reduction (1:39:24) Brain training as the fifth pillar (1:51:52) Memory techniques for names and numbers (2:02:46) Nootropics and supplements for brain health Learn more about your ad choices. Visit podcastchoices.com/adchoices

The 2026 season is barely out of the womb, and we're already blessed with a No. 1 vs. No. 2 matchup in a standalone TV window. You can bet D-Fly & Dixie are excited. With a couple of other Top 20 matchups on tap, this is a loaded show. They are joined by long-time friend of the pod and guest analyst Christian Sweezy, who shares insights on why this is Georgetown's year and discusses his new book, “The Long Red Line.”This week's interview is with Maryland's All-American lockdown defender, Will Schaller. We discuss his hockey background, why he chose Maryland, the benefits of knowledgeable parents, his relationship with Coach Bernhardt, the high expectations for Terps defensemen, pit beef and much, much more. You won't want to miss it.GAME PREVIEWSFRIDAYNo. 1 Maryland (1-0) at No. 2 Syracuse (2-0) | 6 p.m. | ACCN | Maryland -1.5/23.5SATURDAYNo. 14 Penn State (1-1) at No. 3 Princeton (0-0) | noon | ESPN+ | Princeton -4.5/25.5No. 13 Virgina (1-0) at No. 8 Richmond (1-0) | noon | ESPN+ | Richmond -1.5/24.5Loyola (0-1) at No. 14 Johns Hopkins (2-0) | 1 p.m. | ESPN+ live, ESPNU on Feb. 15 | JHU -3.5/22.5No. 4 Cornell (0-0) at UAlbany (0-0) | 1 p.m. | ESPN+ | Cornell -4.5/24.5 GIVE & GOIn this week's Valentine's Day-themed Give & Go, the fellas produce a Top 5 list of their favorite “Love” songs.

IMS debuts its “Be The Best” podcast, which covers the University of Maryland's men's lacrosse program. In this episode, the Terps' 19-10 opening game win over in-state rival Loyola is discussed. Despite slow start on offense, Maryland's transfers from Yale paced the offense, as did a transfer at the face-off X. Younger players getting their first significant experiences also made contributions, as did the return of a goalie who started for the 2024 season. The hosts also do a quick spin around games of national interest - Virginia's win over Colgate, North Carolina's escape against Jacksonville, Villanova's overtime win at Penn State, and others – before getting into a preview of Friday's road tilt against Syracuse. Finally, we note some national games of interest – Virginia at Richmond, Penn State at Princeton, and Loyola at Johns Hopkins. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Dr Bill Nelson talks with Dr Richard Dotson about his book, Unbroken, detailing the story of his diagnosis, treatment, and recovery from pancreatic cancer. Dr Dotson's oncologist at Johns Hopkins, Dr Daniel Laheru, also joins the podcast to discuss his diagnosis and care plan. Learn more about Dr Dotson's book ➡️ https://amzn.to/4qJfVCp

Host Dr. Davide Soldato and guests Dr. David Einstein and Dr. Ravi Madan discuss JCO article, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations," underscoring the need for a consensus on clinical trial designs implementing novel endpoints in this population, the importance of PSA doubling time as a prognostic factor and with an emphasis on treatment de-escalation to limit toxicity and improve patient outcomes. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO authors Dr. David Einstein and Dr. Ravi Madan. Dr. Einstein is a medical oncologist specializing in genitourinary malignancy working at Beth Israel Deaconess Medical Center, part of the DFCI Cancer Center, and an assistant professor at Harvard Medical School. Dr. Madan is a senior clinician at the National Cancer Institute (NCI), where he focuses on conducting clinical research in prostate cancer, particularly in the field of immunotherapy. Today, we will be discussing the article titled, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations." So, thank you for speaking with us, Dr. Einstein and Dr. Madan. David Einstein: Thanks for having us. This is a great pleasure. Ravi Madan: Appreciate being here. Davide Soldato: So, I just want to start from a very wide angle. And the main question is why did you feel that there was the need to convey a consensus and a working group to talk about this specific topic: biochemically recurrent prostate cancer? What has been the change in current clinical practice and in the trial design that we are seeing nowadays? And so, why was it necessary to convey such a consensus and provide considerations on novel clinical trials? David Einstein: Yeah, so I think it's very interesting, this disease state of biochemically recurrent prostate cancer. It's very different from other disease states in prostate cancer, and we felt that there was a real need to define those differences in clinical trials. Years ago, metastatic castration-resistant prostate cancer was the primary disease state that was explored, and over time, a lot of things shifted earlier to metastatic disease defined on a CAT scan and bone scan to an earlier disease state of metastatic castration-sensitive prostate cancer. And the clinical trial principles from late-stage could be applied to MCSPC as well. However, BCR is very different because the patients are very different. And for those reasons, there are unique considerations, especially in terms of toxicity and treatment intensity, that should be applied to biochemically recurrent prostate cancer as opposed to just using the principles that are used in other disease states. And for that reason, we thought it was very important to delineate some of these considerations in this paper with a group of experts. Davide Soldato: Thanks so much. So, one of the main changes that have been applied in recent years in clinical practice when looking at biochemically recurrent prostate cancer is the use of molecular imaging and particularly of PSMA PET. So, first of all, just a quick question: was the topic of the consensus related on which threshold of PSA to use to order a PET scan to evaluate this kind of patient? David Einstein: Yeah, thanks for that question. It's a super important one. The brief answer is that no, we did not address questions about exactly when clinicians would decide to order scans. We were more concerned with the results of those scans in how you define different disease states. But I think as a broader question, I think a lot of folks feel that finding things on a scan equates that with what we used to find on conventional scans. And fundamentally, we actually sought to redefine that disease space as something that's not equivalent to metastatic disease, and rather coined the term "PSMA-positive BCR" to indicate that traditional BCR prognostic criteria and factors still apply, and that these patients have a distinct natural history from those with more advanced metastatic disease. Ravi Madan: And if I may just add that the National Cancer Institute is running a trial where we're prospectively monitoring PSMA-positive BCR patients. And that data is clearly showing that, much like what we knew about BCR a decade ago, PSMA findings in BCR patients do not change the fact that overall, BCR is an indolent disease state. And the findings, which are usually comprised of five- to seven-millimeter lymph nodes, do not endanger patients or require immediate therapy. And so, while PSMA is a tool that we can be using in this disease state, it doesn't really change the principal approach to how we should manage these patients. And as Dr. Einstein alluded to, there is a drive to create a false equivalency between PSMA-positive BCR and metastatic castration-sensitive prostate cancer, but that is not supported by the data we're accumulating or any of the clinical data as it exists. Davide Soldato: One thing that it's very important and you mentioned in your answer to my question was actually the role of PET scan and conventional imaging, so CAT scan and bone scan that we have used for years to stage patients with metastatic prostate cancer. And you mentioned that there is a distinction among patients who have a positive PET scan and a BCR, and patients who have a positive conventional imaging. And yet, we know that sometimes the findings of the PET scan are not always so clear to interpret. So, I just wanted to understand if the consensus reached an agreement as to when to use conventional imaging to potentially resolve some findings that we have on PET scan among thess patients with BCR? David Einstein: Yeah, I think there's a number of questions actually buried within that question. One of which is: does PSMA PET result in false positives? And the answer has definitely been yes. There's a known issue with false-positive rib lesions. And so, first and foremost, we need to be very careful in calling what truly is suspicious disease and what might actually not be cancer or might be something that is totally separate. So I think that's the first part of the answer to that question. The second is to what extent do we need to use paired PET and conventional imaging to define this disease state? In other words, do you have to have positive findings on one and negative findings on the other in order to enter this definition? The challenge there, as we discussed, is that logistically, oftentimes it's hard to get patients to do multiple sets of scans to actually create that definition. Sometimes it's difficult to get insurers to pay for such scans. And finally, it's hard to sometimes blind radiologists to the results of one scan in reading the other. So, we did have some deliberations about to what extent you could use some of the CAT scan portion of a PSMA PET in order to at least partially define that. We also talked about using bone scans to confirm any bone findings seen on PET. But I think another important part of this is not just the baseline imaging, but also what's going to be done serially on a study in order to define responses and progression. And that's sort of a whole separate conversation about to what extent you can interpret changes in serial PET. Ravi Madan: And just to pick up on the key factor here, I think that the PSMA PET in BCR is pretty good at defining lymph node disease, and that's actually predominantly 80 to 90 percent of the disease seen on these findings. It might be pretty good at also defining other soft tissue findings. The real issues come to bone findings. And one thing the group did not feel was appropriate was to just define only PSMA-positive bone findings confirmed on a CT bone window. There's not really great data on that, but the working group felt that, when in the rare situation, because it is relatively rare, a PSMA-positive finding is in a bone, a bone scan should be done. And it's worth noting that Phu Tran, who is a co-author and a co-leader of this working group, his group has already defined that underlying genomics of conventionally based lesions, such as bone scan, are more aggressive than findings on next-gen imaging, such as PSMA. So, there is also a genomic underlying rationale for defining the difference between what is seen on a PET scan in a bone and what is seen on a bone scan. Davide Soldato: Coming back to this issue of PET PSMA sometimes identifying very small lesions where we don't see any kind of correlates on conventional imaging or where we see only very little alteration on the bone scan or in the CT scan, was there any role that was imagined, for example, for MRI to distinguish this type of findings on the PET scan? Ravi Madan: So, I think that, again, what can be identified on a PSMA frequently cannot be seen on conventional imaging. We didn't feel that it was a requirement to get an MRI or a CT to necessarily confirm the PSMA findings. I think that generally, we have to realize that in this disease state, that questionable lesions are going to be seen on any imaging, including PSMA. We've actually probably put way too much faith in PSMA findings thus far, as Dr. Einstein alluded to with some of the false positives we're seeing. So, I think that these false positives are going to have to be baked into trials. And in terms of clinical practice, it highlights the need to again, not overreact to everything we see and not necessarily need to biopsy everything and put patients' health in jeopardy to delineate a disease that's indolent anyway. Davide Soldato: Thanks so much. That was very clear. So, basically, the main driver was really also the data showing that if we have a BCR, so a patient with a biochemically recurrent disease that is positive on the conventional imaging, this is usually associated with a different aggressiveness of the disease. But coming back to a comment that you made before, Dr. Madan, you said that even if we talk about PSMA-positive BCR, we are still talking about BCR and the same criteria should apply. So, what we have used for years in this space to actually try to stratify the prognosis of patients is the PSA doubling time, so how quickly the PSA rises over time. So, coming back to that comment, was the consensus on the PSA doubling time basically retained as what we were using before, so defining patients with a doubling time less than 12 months, 10 months, 9 months, as patients with a higher risk of progressing in terms of developing metastatic disease? Ravi Madan: Yes, so that's a very important point. And the working group defined high-risk BCR as a PSA doubling time less than six months. And this really comes from Johns Hopkins historical data, which shows that if your doubling time is three months or less, there's about a 67 percent chance of metastasis at five years. If it's between three and six months, it's 50 percent. And if it's over six months, if it's between six and nine months, it's roughly only 27 percent. There are trials that are accruing with eligibility criteria that they may describe as high-risk that are beyond six months, but the data as really it's been defined in the literature highlights that truly high-risk BCR is less than six months. And the working group had a consensus on that opinion, and that was our recommendation. David Einstein: And I think an important follow-on to that is that's regardless of PET findings, right? And so, we present a couple of case studies of patients with positive PET findings who have a long doubling time, in whom the disease is in fact indolent, as you would have expected from a traditional BCR prognostic standpoint. Obviously, there are patients in whom they have fast doubling times, and even if they do not have PET findings, that doesn't make them not high-risk. Ravi Madan: And just to follow up that point, I will let you know a little bit of a free preview that my colleague Melissa Abel from the NCI will be presenting PSMA findings in the context of PSA doubling time at ASCO GU if that data is accepted. Davide Soldato: Looking forward for those data because I think that they're going to clarify a lot of the findings that we have in this specific population. And coming back to one of the points that we made before, so PET PSMA has a very high ability to discriminate also a very low burden of disease, which we currently refer to as oligometastatic biochemically recurrent prostate cancer, which is not entirely defined as an entity. But what we are seeing both in some clinical trials, which use mainly conventional imaging, but also what we're starting to see in clinical practice, is that frequently we use the metastasis-directed therapy to treat these patients. So, just a little bit of a comment on the use of this type of strategy in clinical practice and if the panel thought of including this as, for example, a stratification criteria or mandated in the design of novel clinical trials in the field of BCR? David Einstein: Yeah, I think that's an incredibly important point. You know, fundamentally, there's a lot of heterogeneity in practice where some folks are using local salvage approaches, some are using systemic therapies, in some cases surveillance may be reasonable, or some combination of these different strategies. We certainly have phase two data from multiple trials suggesting that met-directed therapy may help buy patients time off of treatment until subsequent treatments are started. And that in and of itself may be an important goal that we can come back to in discussing novel endpoints. I think what our panel acknowledged was that, in some sense, the clinical practice has gotten even farther ahead than where the data are, and this is being offered pretty routinely to patients in practice. And so, what became clear was that we, in developing clinical trials, cannot forbid investigators from doing something that would be within their usual standard of care, even if it might not be supported by the most robust data. But at minimum, it definitely should be used as a stratification factor, or in some trial designs, you can do met-directed therapy after a primary endpoint is assessed. And that offers a compromise between testing, say, the effect of a systemic therapy but also not excluding patients and investigators from doing what they would have done had they not been on a study. Ravi Madan: And I would just like to follow up your phrasing in the question of "oligometastatic prostate cancer." We have a figure in the paper and it highlights the fact that, unfortunately, that term in prostate cancer is imaging agnostic. And we've already discussed in this podcast, as well as in the paper, that imaging used to define a metastatic lesion, whether it's PSMA or conventional imaging, carries with it a different clinical weight and a different prognosis. So, we feel in the working group, that the correct term for this disease state of PSMA-positive BCR is just that: PSMA-positive BCR. We also have to realize that when we talk about oligometastatic disease, while it's imaging agnostic, it seems to be numerically based, whether it's five or three or 10 depending on the trial. But PSMA-positive BCR does not have a limit in terms of the number of lesions. And so again, we just feel that there is an important need to delineate what we're seeing in this disease state, which again is PSMA-positive BCR, and that should be differentiated frankly from oligometastatic disease defined on other imaging platforms. David Einstein: Right, and that also makes clear that patients can have polyfocal disease on PET that still is not what we would consider metastatic, but goes beyond the traditional definition of oligometastatic. So, in other words, just because someone has PET-detected disease only, that does not automatically equate with oligometastatic. Davide Soldato: Thanks so much. So, you were speaking a little bit, Dr. Einstein, about the different types of treatment that we can propose or not propose to this patient because you mentioned, for example, that in clinical practice MDT, so metastasis-directed therapy, is becoming more and more used. For these patients, we can potentially use systemic treatments, which include androgen deprivation therapy, which can be given continuously or in an intermittent fashion. And recently, we can also use novel systemic therapies, for example, enzalutamide, to treat this type of patient. So, given that the point of the consensus was really to provide consideration for novel clinical trials in this space, what was the opinion on the panel regarding the control arm? So, if we're looking at a novel therapy in the BCR space, does the control arm need to include a therapy or not? And if so, which therapy? David Einstein: Yeah, this is a super important question and one that's subject to a lot of discussion, especially in light of recent data from EMBARK. What we came to a consensus around was the fact that neither MDT nor systemic therapy should be required as a control arm on BCR trials. And we can talk about a number of reasons for that. There's also the pragmatics of what investigators might actually accrue patients to and what they would consider their standard of care, and that's important to factor in, too. I think that one of the major goals of our working group was outlining what kinds of trials we would like to see in the future and where the limitations of the current data stand. For example, EMBARK proposes a strategy of a single treatment discontinuation and resumption at a predefined threshold indefinitely. That's probably not how most people are practicing. Most folks are probably using some version of intermittent therapy as they would have before this trial, but we actually don't have any data supporting that. Moreover, we don't have data comparing different intermittent strategies to one another. We don't know what the right thresholds are, we don't know how much time we buy patients off treatment, and we don't know to what extent MDT modifies that. And so, those are all really important questions to be asking in future versions of these trials. I'd say my second point would be that a lot of drug development is happening with novel therapies that are not hormonal, trying to bring them into this space. And when you think about trying to compare one of those types of therapies to a hormonal therapy on short-term endpoints, the hormonal therapy is always going to win. Hormonal therapy is almost universally effective, it will bring down PSAs, and it will prolong, quote-unquote, "progression." The downside of that is that hormonal therapy doesn't actually modify the disease, it suppresses it, and it tends to have fairly transient effects once you remove it. And so, part of our goal was in trying to figure out some novel endpoints that would allow these novel types of therapies to be examined head-to-head against a more traditional type of hormonal therapy and have some measurement of some of the more long-term impacts. Davide Soldato: So, jumping right into the endpoints, because this is a very relevant and I think very well-constructed part of the paper that you published. Because in the past we have used some of these endpoints, for example, metastasis-free survival, as potentially a proxy for long-term outcomes. But is this the right endpoint to be using right now, especially considering that frequently this outcome is measured using conventional imaging, but we are including in these trials patients who are actually negative on conventional imaging but have a positive PSMA when they enter this type of trial? David Einstein: Yeah, there's a number of challenges with those types of endpoints. One of which is, as you say, we're changing the goalposts a little bit on how we're calling progression. We still don't exactly understand what progression on PET means, and so that's something that is challenging. That said, we're also cognizant of the fact that many times investigators are likely to get PET scans in the setting of rising PSA, and that's going to affect any endpoint that relies purely on conventional imaging. So, there's some tension there between these two different sets of goalposts. One thing that we emphasize is that not only are there some challenges in defining those, but also there're challenges in what matters to a patient. So, if a progression event occurs in the form of a single lesion on a PET scan or even a conventional image, that might be relevant for a clinical trial but might be less relevant for a patient. In other words, that's something that, in the real world, an investigator might use serial rounds of metastasis-directed therapy or intermittent therapy to treat in a way that doesn't have any clinical consequences for the patient necessarily. In other words, they're asymptomatic, it's not the equivalent of a metastatic castration-resistant disease progressing. And so, we also need to be cognizant of the fact that if we choose a single endpoint like PFS, that there's going to be many different versions of progression, some of which probably matter clinically more than others, and some of which are more salvageable by local therapies than others. Ravi Madan: So I think the working group really thoughtfully looked at the different options and underscored perhaps strengths and weaknesses, and I think that's presented as you mentioned in the paper. But I think it's also going to depend on the modality, the approach of the therapeutic intervention. In some cases if it's hormone-based, then maybe PSA is providing some early metrics, maybe metastasis-free survival is more relevant in a continuous therapy, but intermittent therapies might have a different approach. There's emerging immunotherapy strategies, radiopharmaceutical strategies, they might have some more novel strategies as well. I think we have to be open-minded here, but we also have to be very clear: we do not know what progression is on a PSMA scan. Just new lesions may not carry the clinical significance that we think, and we may not know what threshold that ultimately becomes clinically relevant is. So, I do think that there was some caution issued by the working group about using PSMA as an endpoint because we still do not have the data to understand what that modality is telling us. Again, I'm optimistic that the National Cancer Institute's prospective data set that we've been collecting, which has over 130 patients now, will provide some insights in the months and years ahead. Davide Soldato: So, just to ask the question very abruptly, what would you feel like the best endpoint for this type of trials is? I understand that is a little bit related to the type of treatments that we're going to use, whether it's intermittent, whether it's continuous, but do we have something that can encapsulate all of the discussion that we have up until this point? David Einstein: Yeah, so that's a perfect segue to the idea of novel endpoints, which we feel are very important to develop in these novel disease spaces. So, one thing that we discussed was an endpoint called treatment-free survival, which conceptually you can think of as exactly what it sounds like, but statistically you actually have to do some work to get there. And so essentially, you imagine a series of Kaplan-Meier curves overlaid: one about overall survival, one time to next therapy, one time on initial therapy. You can actually then take the area under those curves or between those curves and essentially sum it up using restricted mean survival time analysis. And that can give you a guide about the longitudinal experience of a patient: time spent on treatment versus off treatment; time spent with toxicity versus without toxicity. And importantly, each one of those time-to-event metrics can be adjusted depending on exactly what the protocol is and what is allowed or not allowed and what's prespecified as far as initiation of subsequent therapies. So, we felt that this was a really important endpoint to develop in this disease space because it can really capture that longitudinal aspect. It can really reward treatments that are effective in getting durable responses and getting patients off of therapy, because unfortunately, PFS-based endpoints generally reward more or longer systemic therapy versus shorter or no systemic therapy, and that's sort of an artificial bias in the way those endpoints are constructed. So, I think that there are challenges of course in implementing any new endpoint, and some of the things that are really critical are collecting data about toxicity and about subsequent therapies beyond what a typical trial might collect. But I think in this kind of disease space, that longitudinal aspect is critical because these are really patients who are going to be going through multiple rounds of therapy, going to be going on and off treatments, they're going to be using combinations of local and systemic therapies. And so, any one single endpoint is going to be limited, but I think that really highlights the limitations of using PFS-based endpoints in this space. Ravi Madan: I also think that in the concept of treatment-free survival lies one of the more powerful and, honestly, I was surprised by this, that it was so universally accepted, recommendations from the committee. And that was that the general approach to trials in this space should be a de-escalation of the EMBARK strategy as it's laid out with relatively continuous therapy with one pause. And so, I think again, buried in all of this highlights the need for novel endpoints like treatment-free survival. We get to the fact that these are patients who are not at near-term clinical risk from symptoms of their disease, so de-escalating therapies does not put them at risk. And if you look at, for example, lower-volume metastatic castration-sensitive prostate cancer, it's become realized that we need to de-escalate, and there are now trials being done to look at that. Historically, we know that BCR is an indolent disease process for the vast majority of patients who are not at near-term risk from clinical deterioration. So, therefore, we shouldn't wait a decade into abundant BCR trials to de-escalate. The de-escalation strategy should be from the outset. And that was something the committee really actually universally agreed on. David Einstein: And that de-escalation can really take multiple forms. That could be different strategies for intermittent therapy, different start-stop strategies. It could also mean actually intensifying in the short-term with the goal long-term de-intensification, kind of analogous to kidney cancer where we might use dual checkpoint inhibitors up front with some higher upfront toxicity but with the hope of actually long-term benefit and actually being able to come off treatment and stay in remission. Those kinds of trade-offs are the types of things that are challenging to talk about. There's not a one-size-fits-all answer for every patient. And so, that's why some of these endpoints like treatment-free survival would be really helpful in actually quantifying those trade-offs and allowing each patient to make decisions that are concordant with their own wishes. Davide Soldato: Thanks so much. That was very clear, especially on the part of de-escalation, because, as you were mentioning, I think that we are globally talking about a situation, a clinical situation, where the prognosis can be very good and patients can stay off treatment for a very long period of time without compromising long-term outcomes. And I think that well-constructed de-escalation trials, as you were mentioning and as the consensus endorsed, are really needed in this space also to limit toxicity. This brings us to the end of this episode. So, I would like to thank again Dr. Einstein and Dr. Madan for joining us today. David Einstein: We really appreciate the time and the thought, and I think that even starting these types of discussions is critical. Even just recognizing that this is a unique space is the beginning of the conversation. Ravi Madan: Yeah, and I want to thank JCO for giving us this forum and the opportunity to publish these results and all the expert prostate cancer investigators who were part of this committee. We produced some good thoughts for the future. Davide Soldato: We appreciate you sharing more on your JCO article titled, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Olufunmilayo “Funmi” Olopade, director for the Center for Clinical Cancer Genetics and Global Health at the University of Chicago, credits her Nigerian upbringing for her focus on global cancer genetics.“My Yoruba culture really worships our ancestors and the people before us,” Olopade said on the Cancer History Project podcast. “And so that's why I was able to really say, ‘Okay, let's lay the foundation for genetics. Let's go to Nigeria.'”Olopade appears on this special Black History Month episode of the Cancer History Project Podcast in conversation with Robert A. Winn, director and Lipman Chair in Oncology at VCU Massey Comprehensive Cancer Center and guest editor for The Cancer Letter for Black History Month highlighting some of the giants in the field of cancer research.This episode is sponsored by City of Hope, the American Society of Clinical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and the University of Texas MD Anderson Cancer Center.Olopade is certainly a giant in cancer genetics and global health.“For those of you who don't know, Dr. Olopade is not only the director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago, but she is really a giant in the field and internationally renowned in the context of her expertise in breast cancer,” Winn said on the podcast. “By the way, for those of you who thought you knew Dr. Olopade, remember that she is a really rare, not only National Academy, but in that top 1% of 1% of the 2025 MacArthur Fellowship, also known as the Genius Grant.”On this episode of the Cancer History Project Podcast, Olopade shares her story of immigrating to the U.S. from Nigeria to pursue medicine, and finding her way to becoming a leading expert in oncology.“For us to honor Black History Month, we have to honor all the people who mentored us, who were ahead of us,” Olopade said. “For me, my father was a pastor, and my parents really wanted a doctor. I had big brothers and sisters, I was number 5 of 6 children, and there was just one last chance to find a doctor in the family. Because in those days, growing up in Nigeria, you were either a teacher or a pastor, or and then in his generation he became a pastor.”Growing up in Nigeria, Olopade was deeply influenced by the health disparities she saw due to lack of healthcare access, which initially sparked an interest in cardiology.Explore related articles and read the full transcript: https://cancerhistoryproject.com/article/funmi-olopade-podcast/ 

Tom opens this week's livestream with updates and announcements:Registration remains open for the New Biology Experience at Polyface Farm (June 2026). Tom reminds the audience there's still time to sign up and join him, the New Biology Clinic team, and community members for a weekend of talks, food, music, and connection.New Biology Experience link here.In honor of Heart Month, DrTomCowan.com is offering a Heart Health Sale on:Hibiscus Concentrate and Human Heart, Cosmic Heart book.This sale ends TONIGHT at 11:59 PM PT.This week's science news includes:-A satirical open letter to Vernon Coleman and the announcement of his nomination for the “Put-sky Gas Bag of the Year” award-A Johns Hopkins study linking hydrogen sulfide (fart gas) to Alzheimer's prevention-A claim that the shingles vaccine slows aging and dementia-Evolution “going into overdrive” exactly 66 million years ago-A new mRNA-based sickle cell “cure” priced at $3 millionA thoughtful Q&A on:-Are chemtrails real? And if so, how should we go about detoxifying from chemtrails?-Is it OK to blend foods?-Why do people get kidney stones and what can you do to prevent them?-What are warts and what is their purpose?-Is shedding real?-What about cataracts?-Somebody asked about getting a superficial fungal infection—usually in places like your groin or your armpit, or sometimes what's called athlete's foot.Support the showWebsites:https://drtomcowan.com/https://www.drcowansgarden.com/https://newbiologyclinic.com/https://newbiologycurriculum.com/Instagram: @TalkinTurkeywithTomFacebook: https://www.facebook.com/DrTomCowan/Bitchute: https://www.bitchute.com/channel/CivTSuEjw6Qp/YouTube: https://www.youtube.com/channel/UCzxdc2o0Q_XZIPwo07XCrNg

When 84-year-old Nancy Guthrie disappeared from her home, investigators were quickly faced with blood evidence and ransom claims that did not align with standard abduction patterns. In this episode of Zone 7, Sheryl McCollum, retired NYPD homicide detectives Dan Murphy and Tom Smith, and forensic pathologist Dr. Priya Banerjee assess why blood at the scene, a prolonged presence inside the home, and Nancy’s medical vulnerabilities undermine the ransom narrative. The panel also examines investigative decisions and evidence handling that may shape accountability. For those looking to catch up further as the situation develops, additional coverage and updates can be found on Crime Stories with Nancy Grace. Highlights: • (0:00) Sheryl McCollum welcomes listeners, introduces the Nancy Guthrie case, and brings in Dan Murphy, Tom Smith, and Dr. Priya Banerjee • (1:30) Savannah Guthrie’s early silence and why not using her platform immediately raised concern • (2:15) Blood at the scene, smashed cameras, and why this should have been treated as an abduction from the start • (4:15) Interior crime scenes, early release, and how evidence integrity can be compromised • (4:45) Dr. Priya Banerjee on age, blood thinners, cardiac disease, and stress-related death • (7:15) The 41-minute timeline inside the home and why it defies kidnapping patterns • (8:30) Delayed ransom demands, media involvement, and why the timing doesn’t track • (12:15) Lights left on inside the house and behavior inconsistent with covert abduction • (13:30) Bitcoin ransom logic and why mixed-payment demands raise red flags • (14:15) A robbery-gone-wrong scenario and what happens if the victim recognizes the offenders • (16:15) Chronic pain, medication dependency, and why prolonged captivity is medically unlikely • (19:00) Family video statements, proof-of-life questions, and linguistics shifts investigators notice • (21:00) Reactionary law enforcement activity and repeated returns to the scene • (24:30) Pacemakers, Apple Watch connectivity, and what technology may still reveal • (28:30) Leadership optics, media interference, and the impact of active investigations • (36:45) Reward amounts, chain of custody concerns, and courtroom implications • (41:30) Final thoughts from the panel on recovery efforts, investigative outlook, accountability, and why Sheryl believes it was never about the money Guest Bio: Dr. Priya Banerjee is a board-certified forensic pathologist with extensive experience in death investigation, clinical forensics, and courtroom testimony. A graduate of Johns Hopkins, she served for over a decade as Rhode Island’s state medical examiner and now runs a private forensic pathology practice. Dan Murphy is a retired NYPD Detective-Sergeant with extensive experience in homicide, major case investigations, and counterterrorism. During his career, he served in units including the Major Case Squad and the FBI/NYPD Joint Terrorism Task Force. Since retiring from law enforcement, Dan has served as Chief Security officer for U.S. Bancorp, co-authored Workplace Safety: Establishing an Effective Violence Prevention Program, and co-hosts the podcast Gold Shields. Tom Smith is a retired NYPD detective and 2024 National Law Enforcement Hall of Fame inductee. Over 30 years of service, he worked in patrol, narcotics, and robbery investigations and spent 17 years working with the FBI/NYPD on the Joint Terrorism Task Force, including an overseas deployment to Afghanistan. Tom co-hosts the podcast Gold Shields, lectures on criminal justice and terrorism, and provides investigative commentary for national media outlets. Enjoying Zone 7? Leave a rating and review where you listen to podcasts. Your feedback helps others find the show and supports the mission to educate, engage, and inspire. Sheryl “Mac” McCollum is an active crime scene investigator for a Metro Atlanta Police Department and the director of the Cold Case Investigative Research Institute, which partners with colleges and universities nationwide. With more than 4 decades of experience, she has worked on thousands of cold cases using her investigative system, The Last 24/361, which integrates evidence, media, and advanced forensic testing. Her work on high-profile cases, including The Boston Strangler, Natalie Holloway, Tupac Shakur and the Moore’s Ford Bridge lynching, led to her Emmy Award for CSI: Atlanta and induction into the National Law Enforcement Hall of Fame in 2023. Social Links: • Email: coldcase2004@gmail.com • Twitter: @ColdCaseTips • Facebook: @sheryl.mccollum • Instagram: @officialzone7podcast Preorder Sheryl’s upcoming book, Swans Don’t Swim in a Sewer: Lessons in Life,Justice, and Joy from a Forensic Scientist, releasing May 2026 from Simon and Schuster. https://www.simonandschuster.com/books/Swans-Dont-Swim-in-a-Sewer/Sheryl-Mac-McCollum/9798895652824 See omnystudio.com/listener for privacy information.

In this episode of Preconceived, Zale explores the often misunderstood topic of infidelity, revealing why cheating is more common and psychologically complex than it appears on the surface. Joined by Dr. Dylan Selterman, a Johns Hopkins psychology professor, this discussion uncovers the motivations, psychological factors, and societal influences around cheating in relationships. Notably, the episode delves into the surprising revelation that many individuals do not regret cheating, examining the underlying psychological and emotional factors that contribute to this mindset.Learn more about Dylan Selterman at https://www.dylanselterman.com/ Hosted on Acast. See acast.com/privacy for more information.

In his weekly clinical update during Ground hog week, Dr. Griffin and Vincent Racaniello are back to discuss the measles outbreak in South Carolina, American Academy of Pediatrics vaccine recommendations and shingles vaccine and the reduction of dementia, then deep dives into recent statistics RSV, influenza and SARS-CoV-2 infections, the Wastewater Scan dashboard, Johns Hopkins measles tracker, where to find PEMGARDA, how to access and pay for Paxlovid, estimated effectiveness of this year's COVID-19 vaccine, long COVID treatment center, where to go for answers to your long COVID questions, long COVID in children, the potential benefits of metformin to reduce disease severity following SARS-CoV-2 infection in obese and overweight patients and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Grading the groundhogs (National Oceanic and Atmospheric Administration) Sand Mountain Sam predicts an early spring (News19) All About the AAP Recommended Immunization Schedule (healthychildren.org) Recommended Childhood and Adolescent Immunization Schedule: United States, 2026: Policy Statement (American Academy of Pediatrics: Pediatrics) Herpes zoster vaccination and incident dementia in Canada: an analysis of natural experiments (LANCET: Neurology) Detection of avian flu antibodies in Dutch dairy cow: ECDC risk assessment remains unchanged (European Centre for Disease Prevention and Control) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard(South Carolina Department of Public Health) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles(CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option(xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Estimated Effectiveness of 2024-2025 COVID-19 Vaccination Against Severe COVID-19 (JAMA) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study (LANCET: Infectious Diseases) Long COVID is here to stay—even in children (LANCET: Infectious Diseases) Early administration of neutralising monoclonal antibodies and post-acute sequelae of COVID-19 (International Journal of Infectious Diseases) Preventing Long COVID With Metformin (CID) Metformin may reduce risk of long COVID by 64% in overweight or obese adults (CIDRAP) Effect of Metformin on the Risk of Post-coronavirus Disease 2019 Condition Among Individuals With Overweight or Obese (CID) Preventing Long COVID With Metformin (CID) New review highlights growing evidence that diabetes drug metformin can prevent long COVID (CIDRAP) Reaching out to US house representative Letters read on TWiV 1294 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

In this episode, Hunt Priest joins to discuss the intersection of psychedelic experiences and religion. Hunt is the founder of Ligare: A Christian Psychedelic Society and was a participant in the Johns Hopkins/NYU Psilocybin Study for Religious Leaders in 2016. The epiphanies he had at Hopkins forever changed the trajectory of his work and led him to start Ligare in 2021. In this conversation, Hunt Priest reflects on how participating in the Johns Hopkins study reshaped his understanding of Christianity, embodiment, and spiritual experience. Drawing on his background as an Episcopal priest, he explores the deep resonance between psychedelic experiences and Christianity, arguing that non-ordinary states of consciousness have always been central to religious life, even if institutional churches have often marginalized them. The discussion ranges from spiritual emergence and theological disruption to healing, discernment, and the role clergy can play in preparation and integration. Hunt also shares his own profound embodied experience during the study where he encountered Vedic and Upanishadic concepts firsthand. He explains how it ultimately led him to found Ligare, a Christian psychedelic society aimed at bridging psychedelics, healing, and the Christian mystical tradition.   In this episode, you'll hear: Hunt's ideas of how psychedelic experiences connect with Christian sacraments and liturgical practices How psychedelics connect with understandings of religious pluralism and the diversity of spiritual experiences Resources for working through ideas that psychedelic experiences could be sinful or demonic Hunt's thoughts on navigating theological disruption, spiritual emergence, and expanded images of God Why embodiment and bodily wisdom are central to spiritual insight and healing The vital opportunity institutional religion risks missing in the current psychedelic renaissance   Quotes: "I think there's a lot of us [clergy] out there that understand that the spiritual issues that come up with psychedelics are important and need to be tended to in a sensitive way—in an open minded way, an open hearted way." [14:36] "The Church has, over time, taught people to not trust their minds or their bodies. And that's a huge mistake because our bodies keep the score and they also are one of the places we hold wisdom—which was the biggest lesson I got from the first experience I had at Hopkins." [17:39] "That's why the spiritual care professionals could be so important: when these issues, these spirit big spiritual questions or even a collapse of your own theological framework happens, you need help to put it back together. And just like therapy helps us put our emotional life back together, I think a good spiritual director or spiritual advisor—one-on-one or small group work—can help us put our theology back together." [21:47]   Links: Ligare website Ligare on Instagram Hunt on Instagram Hunt on LinkedIn Center for Action and Contemplation website Previous episode: Avoiding the Pitfalls of Psychedelic Medicine with Matthew Johnson, PhD Psychedelic Medicine Association Porangui  

"Without our health, we don't have anything." Join host Heather in this deeply personal and enlightening episode of Health, Harmony and Heather as she sits down with Jim Curtis—author, motivational speaker, and health tech innovator. Jim shares his harrowing and inspiring journey of battling a mysterious, undiagnosed chronic illness 20 years ago that eventually left him in a wheelchair. From searching for answers at Johns Hopkins to learning from Kung Fu masters and shamans, Jim discusses how he moved past despair and pain to reverse his condition through a shift in mindset and functional medicine. In this episode, we explore: The "Anti-Inflammatory Mindset": How mental inflammation can be more destructive than physical inflammation. The Stimulati Experience: Discovering the "stimuli"—the extraordinary people and minds that ignite our passion and propel us toward healing. Bio-Individuality: Why there is no "silver bullet" and how to find the specific diet and lifestyle hacks (from cold therapy to grounding) that work for your unique DNA. Navigating Big Food & Pharma: Understanding how marketing impacts our health and why we must become advocates who "question our doctors". The Power of Breath: Practical tips on nasal breathing and the "box breathing" technique to lower stress and oxygenate your body. Whether you are dealing with a health setback or simply looking to "crowd out" bad habits with better ones, this conversation provides a roadmap for taking your life into your own hands. Book: The Stimulati Experience: 9 Skills for Getting Past Pain, Setbacks and Trauma to Ignite Health and Happiness Instagram: @JimCurtis1 Health, Harmony and Heather is dedicated to enriching life perspectives by exploring social phenomena, the human condition, and our connection to ourselves and the planet. We dive into physical, mental, and spiritual health to help you find your innermost truth, happiness, and freedom. Website: ⁠www.heatherthomson.com⁠ You Tube: ⁠https://youtube.com/@iamheathert?si=ZvI9l0bhLfTR-qdo⁠ Inquiries about this podcast: ⁠Karin@sireniamedia.com⁠ Social media:  IG: ⁠https://www.instagram.com/iamheathert/⁠ #HealthAndHarmony #JimCurtis #FunctionalMedicine #ChronicPainRecovery #Biohacking #IntegrativeNutrition #MindsetShift   Learn more about your ad choices. Visit megaphone.fm/adchoices

Watch every episode ad-free & uncensored on Patreon: https://patreon.com/dannyjones Diane Hennacy, M.D. is a Johns Hopkins-trained neuropsychiatrist and neuroscientist, former Harvard faculty member, and an award-winning author and clinician. She began studying autism in 1987, when she spent six months with Sir Michael Rutter at the Institute for Psychiatry in London. Her decades long research focused on investigating reports of telepathy and precognition in autistic children was the inspiration for The Telepathy Tapes. SPONSORS https://mizzenandmain.com - Use code DANNY20 for 20% off your first order. https://prizepicks.onelink.me/LME0/DANNY - Use code DANNY & get $50 in lineups when you play your first $5 lineup! https://amentara.com/go/DJ - Use code DJ22 for 22% off your first order. https://shopmando.com - Use code DANNY for 20% off + free shipping. https://whiterabbitenergy.com/?ref=DJP - Use code DJP for 20% off EPISODE LINKS https://drdianehennacy.com https://hennacyinstitute.org FOLLOW DANNY JONES https://www.instagram.com/dannyjones https://twitter.com/jonesdanny OUTILNE 00:00 - How a Johns Hopkins trained psychiatrist got into ESP 04:46 - Savant Syndrome 06:48 - Why psychiatry disagrees with parapsychology 07:20 - Working down the hall from John Mack 11:28 - Why Diane wanted to be a neurosurgeon 16:34 - Where memory is stored in the brain 18:42 - Hippocampus' role in memory & ESP 25:51 - How oxygen deprivation destroys memory 30:49 - Harmful brain effects of breath-holding 32:14 - Effects of ketogenic state on the brain 35:25 - The autism & telepathy connection 39:44 - Savant Syndrome in blind & autistic individuals 45:51 - Neuroscience is a flawed model 51:06 - The analytical couch & the root of psychiatry 57:45 - How to prove or disprove ESP phenomena 01:01:57 - 97% accuracy telepathy test 01:11:21 - Possible materialist explanation for autistic ESP 01:16:25 - Why autistic individuals are more likely to experience ESP 01:25:25 - The problems with memory 01:26:50 - People who can't forget anything (hyperthymesia) 01:30:41 - White matter in the brain 01:34:48 - Microtubules & consciousness 01:40:53 - How to advance microtubule research 01:43:00 - Ultrasound as Alzheimer's therapy 01:45:30 - Applications of infrared light therapy 01:54:12 - The body's internal "fiber optic" system 01:58:21 - Human's natural telepathic abilities have atrophied over time 02:01:17 - Schools are failing our youth 02:05:13 - Ancient humans' telepathic abilities 02:09:45 - How the bible warns against the written word 02:15:09 - Autistic telepathic kids who mention bible characters 02:19:43 - The sixth sense humans have buried inside them 02:24:02 - The hidden superpowers of the nose 02:28:36 - How your nose can smell true love 02:32:23 - The new split in human evolution 02:35:32 - Proof of technologically advanced ancient humans 02:40:59 - The filter hypothesis 02:48:10 - Disproving the materialist model 02:51:38 - Non-autistic people with ESP 02:54:20 - Autistic people who see dead people Learn more about your ad choices. Visit podcastchoices.com/adchoices

Brain organoids, cell collections grown in a lab to study diseases like Alzheimer's, have created excitement because they are a bit more representative of a real brain. Johns Hopkins cell engineering expert Vasiliki Machairaki says there is another technique underway … What is an assembloid? Elizabeth Tracey reports Read More »

A simple blood test may soon help precisely identify your risk for Alzheimer's disease by inducing some of your cells to go back in time, looking like they did when you were an embryo. Johns Hopkins cell engineering expert Vasiliki … What might reprogramming cells have to do with understanding Alzheimer's? Elizabeth Tracey reports Read More »

Stem cells used to be derived from human embryos, but not anymore. Now a simple blood test can allow stem cells to be induced from cells found there, says Johns Hopkins cell engineering expert Vasiliki Machairaki. Machairaki: Induced pluripotent stem … How do stem cells derived from blood differ from those from embryos? Elizabeth Tracey reports Read More »

In his weekly clinical update, Dr. Griffin and Vincent Racaniello discuss with disgust the decline and fall of American public health and the rise of "only me" when highlighting completion of the US withdrawal from the WHO and possibility of making IPV and MMR optional vaccines, before Dr. Griffin then deep dives into recent statistics RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, Europe losing its measles elimination status, first measles death in Mexico, almost 1000 measles cases in South Carolina, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, the effectiveness of this season's influenza vaccine, where to go for answers to your long COVID questions and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode US completes withdrawal from World Health Organization (AP News) Rejecting Decades of Science, Vaccine Panel Chair Says Polio and Other Shots Should Be Optional (NY Times) A Frightening Interview (Beyond the Noise) Unexplained Pauses in Centers for Disease Control and Prevention Surveillance: Erosion of the Public Evidence Base for Health Policy (Annals of Internal Medicine) Wastewater for measles (WasterWater Scan) UK among 6 European countries losing measles elimination status (Dougall MD: DG Alerts) European Regional Verification Commission for Measles and Rubella Elimination (RVC) (WHO: Europe) Measles Outbreak Associated with an Infectious Traveler — Colorado, May–June 2025 (CDC: MMWR) South Carolina measles cases hit 789, surpassing Texas' 2025 outbreak total (Reuters) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) States across the country report first measles cases of year(CIDRAP) First measles death confirmed in Mexico in 2026 (Mexico News) Influenza: Waste water scan for 11  pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: cliff notes (CDC FluView) Influenza Vaccine Effectiveness Among Children With and Without Underlying Conditions(Pediatrics) OPTION 2: XOFLUZA $50 Cash Pay Option(xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Effectiveness and Durability of the BNT162b2 KP.2 vaccine against COVID-19 Hospitalization and Emergency Department or Urgent Care Encounters in US Adults (OFID) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Association of Nirmatrelvir-ritonavir with intubation or mortality risks in severe COVID-19 patients (BMC Infectious Diseases) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1292 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

We don't need to hide.Our guest this week shares this message loud and clear: as providers, we have nothing to hide from our patients.Dr. Erica Urquhart knows a thing or two about our healthcare system - having trained at Harvard as a biomedical engineer, she received a MD-PhD in Molecular and Neuroscience from Johns Hopkins and is now a practising orthopedic surgeon.She joins today to talk through her outlook on a broken system, as told in her upcoming book ‘Invisible Hand Wielding the Scalpel: Paying the Price in America's Fractured Healthcare System'.—We spoke about the value of transparency in healthcare, her constant battle with massive insurance companies, the capitalist emphasis in the system, the influence of commercial insurers in driving the cost and accessibility of care, and the fundamental importance of sickness prevention.Follow me on Instagram and Facebook @ericfethkemd and checkout my website at www.EricFethkeMD.com. My brand new book, The Privilege of Caring, is out now on Amazon! https://www.amazon.com/dp/B0CP6H6QN4

What if psychedelics could transform the way we treat trauma, chronic pain, and insomnia? This week, neuroscientist and psychedelic researcher Grace Blest-Hopley joins the show to break down the research on psychedelics and female biology. She discusses how psychedelics work in the brain, and the ways that psychedelic-assisted therapies might be beneficial for women in midlife. Links to resources mentioned in this episode: Hystelica’s resources on psychedelic retreats The Heroic Hearts Project Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings The acute effects of classic psychedelics on memory in humans Psilocybin with psychological support for treatment-resistant depression: six-month follow-up Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Johns Hopkins study on psychedelics and Alzheimer’s Note: In this show, we use “women” as shorthand for people with XX chromosomes. We understand sex and gender are more complex, and acknowledge the experiences we describe reach beyond that word.See omnystudio.com/listener for privacy information.

On this week’s episode, we’re continuing our Guidelines Series exploring the 2022 ESC/ERS Guidelines for the diagnosis and treatment of Pulmonary Hypertension. If you missed our first episode in the series, give it a listen to hear about the most recent recommendations regarding Pulmonary Hypertension definitions, screening, and diagnostics. Today, we’re talking about the next steps after diagnosis. Specifically, we’ll be discussing risk stratification, establishing treatment goals, and metrics for re-evaluation. We’ll additionally introduce the mainstays of pharmacologic therapy for Pulmonary Hypertension. Meet Our Co-Hosts Rupali Sood  grew up in Las Vegas, Nevada and made her way over to Baltimore for medical school at Johns Hopkins. She then completed her internal medicine residency training at Massachusetts General Hospital before returning back to Johns Hopkins, where she is currently a pulmonary and critical care medicine fellow. Rupali’s interests include interstitial lung disease, particularly as related to oncologic drugs, and bedside medical education. Tom Di Vitantonio  is originally from New Jersey and attended medical school at Rutgers, New Jersey Medical School in Newark. He then completed his internal medicine residency at Weill Cornell, where he also served as a chief resident. He currently is a pulmonary and critical care medicine fellow at Johns Hopkins, and he’s passionate about caring for critically ill patients, how we approach the management of pulmonary embolism, and also about medical education of trainees to help them be more confident and patient centered. Key Learning Points 1) Episode Roadmap How to set treatment goals, assess symptom burden, and risk-stratify patients with suspected/confirmed pulmonary arterial hypertension (PAH). What tools to use to re-evaluate patients on treatment Intro to major PAH medication classes and how they map to pathways. 2) Case-based diagnostic reasoning Patient: 37-year-old woman with exertional dyspnea, mild edema, abnormal echo, telangiectasias + epistaxis → raises suspicion for HHT (hereditary hemorrhagic telangiectasia) and/or early connective tissue disease. Key reasoning move: start broad (Groups 2–5) and narrow using history/exam/testing. In a young patient without obvious left heart or lung disease, think more about Group 1 PAH (idiopathic/heritable/associated). HHT teaching point: HHT can cause PH in more than one way: More common: high-output PH from AVMs (often hepatic/pulmonary) Rare (1–2% mentioned): true PAH phenotype (vascular remodeling; associated with ALK1 in some patients), behaving like Group 1 PAH. 3) Functional class assessment WHO Functional Class: Class I: no symptoms with ordinary activity, only with exertion Class II: symptoms with ordinary activity Class III: symptoms with less-than-ordinary activity (can't do usual chores/shopping without dyspnea) Class IV: symptoms at rest Practical bedside tip they give: Ask if the patient can walk at their own pace or keep up with a similar-age peer/partner. If not, think Class II (or worse). 4) Risk stratification at diagnosis: why, how, and which tools Big principle: treatment choices are driven by risk, and the goal is to move patients to low-risk quickly. ESC/ERS approach at diagnosis (as described): Use a 3-strata model predicting 1-year mortality: Low: 20% ESC/ERS risk assessment variables (10 domains discussed): Clinical progression, signs of right heart failure, syncope WHO FC Biomarkers (NT-proBNP) Exercise capacity (6MWD) Hemodynamics Imaging (echo; sometimes cardiac MRI) CPET (peak VO₂; VE/VCO₂ slope) They note: even if you don't have everything, the calculator can still be useful with ≥3 variables. REVEAL 2.0: Builds on similar core variables but adds further patient context (demographics, renal function, BP, DLCO, etc.) Case result: both tools put her in intermediate risk (ESC/ERS ~1.6; REVEAL 2.0 score 8), underscoring that mild symptoms can still equal meaningful mortality risk. 5) Treatment goals and follow-up philosophy What they explicitly prioritize: Help patients feel better, live longer, and stay out of the hospital Use risk tools to communicate prognosis and to track improvement Reassess frequently (they mention ~every 3 months early on) until low risk is achieved “Time-to-low-risk” is an important treatment goal Also emphasized: The diagnosis is psychologically heavy; patients need clear counseling, reassurance about the plan, and connection to support groups. 6) Medication classes for the treatment of PAH Nitric oxide–cGMP pathway PDE5 inhibitors: sildenafil, tadalafil Soluble guanylate cyclase stimulator: riociguat Important safety point: don't combine PDE5 inhibitors with riociguat (risk of significant hypotension/hemodynamic effects) Endothelin receptor antagonists (ERAs) “-sentan” drugs: bosentan (less used due to side effects/interactions), ambrisentan, macitentan Teratogenicity emphasized Hepatotoxicity that requires LFT monitoring Can cause fluid retention and peripheral edema Prostacyclin pathway Prostacyclin analogs/agonists: Epoprostenol (potent; short half-life; IV administration) Treprostinil (IV/SubQ/oral/inhaled options) Selexipag (oral prostacyclin receptor agonist) 7) Sotatercept (post-guidelines) They note sotatercept wasn't in 2022 ESC/ERS but is now “a game changer” in practice: Mechanism: ligand trap affecting TGF-β signaling / remodeling biology Positioned as potentially more disease-modifying than pure vasodilators Still evolving: where to place it earlier vs later in regimens is an active question in the field 8) How risk category maps to initial treatment intensity General approach they outline: High risk at diagnosis: parenteral prostacyclin (IV/SubQ) strongly favored, often aggressive early Intermediate risk: at least dual oral therapy (typically PDE5i + ERA); escalate if not achieving low risk Low risk: at least one oral agent; many still use dual oral depending on etiology/trajectory For the case: intermediate-risk → start dual oral therapy (they mention tadalafil + ambrisentan as a typical choice), reassess in ~3 months; add a third agent (e.g., selexipag/prostacyclin pathway) if not low risk.  References and Further Reading Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237. Erratum in: Eur Heart J. 2023 Apr 17;44(15):1312. doi: 10.1093/eurheartj/ehad005. PMID: 36017548. Condon DF, Nickel NP, Anderson R, Mirza S, de Jesus Perez VA. The 6th World Symposium on Pulmonary Hypertension: what’s old is new. F1000Res. 2019 Jun 19;8:F1000 Faculty Rev-888. doi: 10.12688/f1000research.18811.1. PMID: 31249672; PMCID: PMC6584967. Maron BA. Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer. J Am Heart Assoc. 2023 Apr 18;12(8):e029024. doi: 10.1161/JAHA.122.029024. Epub 2023 Apr 7. PMID: 37026538; PMCID: PMC10227272. Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M; STELLAR Trial Investigators. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6. PMID: 36877098. Ruopp NF, Cockrill BA. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. 2022 Apr 12;327(14):1379-1391. doi: 10.1001/jama.2022.4402. Erratum in: JAMA. 2022 Sep 6;328(9):892. doi: 10.1001/jama.2022.13696. PMID: 35412560.

Episode Summary: In this conversation, Kimberly and Josh Redd delve into the critical topic of inflammation, exploring its prevalence, symptoms, and the various health conditions it can exacerbate, including autoimmune diseases and fertility issues. They discuss the impact of diet, gut health, and environmental toxins on inflammation, as well as the promising role of stem cell therapy in managing chronic inflammatory conditions. The conversation emphasizes the importance of education and proactive health management, encouraging listeners to take control of their health through informed lifestyle choices.Chapters00:00 The Rise of Inflammation Awareness03:04 Understanding Inflammation Symptoms05:59 Inflammation's Impact on Children09:00 Autoimmunity and Inflammation12:02 Dietary Influences on Inflammation14:51 The Role of Gut Health17:59 Environmental Toxins and Inflammation21:30 Big Picture Health Strategies23:53 Cooking and Nutrition Control25:25 Understanding Stem Cell Therapy28:56 Stem Cells and Inflammation31:55 Innovations in Stem Cell Treatments34:19 Insurance and Accessibility of TreatmentsSponsors: FATTY15 OFFER: Fatty15 is on a mission to replenish your C15 levels and restore your long-term health. You can get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/KIMBERLY and using code KIMBERLY at checkout.USE LINK: fatty15.com/KIMBERLYDr. Josh Redd Resources: Book: THE 30-DAY INFLAMMATORY RESET: A Complete Guide to Healing Your Immune System Website: DrJoshRedd.com Tik Tok: drjoshred Instagram: @drjoshredd Bio: Dr. Josh Redd, NMD, MS, MPHb, is an industry leader in functional and personalized medicine. With over 12 years of post-graduate education—including two master's degrees and two doctorate degrees—he brings an unmatched depth of training and experience to his patients. His expertise in regenerative medicine includes over 1,000 precision-guided injections for spinal, joint, and soft tissue treatment, helping athletes and active individuals optimize performance and accelerate recovery. He holds an MS in Human Nutrition and Functional Medicine, an MPHb from Johns Hopkins (with an emphasis on molecular biology and immunology), and a Doctor of Chiropractic from Parker University. Most recently, he graduated from naturopathic medical school and completed his residency in regenerative medicine and stem cell injections through Bastyr University.Dr. Redd is the founder of RedRiver Health & Wellness, one of the largest functional medicine clinics in the U.S., with eight locations across Utah, New Mexico, Nevada, and Idaho, and PalmaVita Clinic, a regenerative medicine and athletic performance center in Spanish Fork, Utah.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Hormone therapy is not a panacea for everything that happens to a women transitioning through menopause, cautions Wen Shen, a menopause expert at Johns Hopkins. Now that the FDA has removed their black box warning from many forms of hormone … What are the benefits of hormone therapy for women in menopause and perimenopause? Elizabeth Tracey reports Read More »

If you're a woman who's experiencing a loss of libido, you may have been advised to take testosterone supplements, but Wen Shen, a menopause expert at Johns Hopkins, says wholesale embrace of hormone therapy isn't for everyone, in spite of … Women need to exercise caution when it comes to hormones of all types, Elizabeth Tracey reports Read More »

Hormone therapy for menopause has recently had a black box warning removed by the FDA, after the agency reexamined data originally prompting the warning and found it flawed. Wen Shen, a menopause expert at Johns Hopkins, says women still need … Caveat emptor when it comes to hormone therapy for menopause, Elizabeth Tracey reports Read More »

In his weekly clinical update, Dr. Griffin and Vincent Racaniello discuss screwworm, how the shingles vaccination slows biological aging (for all of you who want to reset 'the clock' and live forever…..you know who you are Musk, Bezos) and getting one dose of the HPV vaccine, then Dr. Griffin then deep dives into recent statistics on RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, how losing our elimination status is the cost of doing business (going for broke is never a good business model !) where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, the effectiveness of this season's influenza vaccine, where to go for answers to your long COVID questions and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode New World Screwworm: Outbreak Moves into Northern Mexico……with an official tag "This is an official CDC Health Advisory" (CDC: Health Alert Network) Association between shingles vaccination andslower biological aging: Evidence from a U.S. population-based cohort study (The Journals of Gerontology series A) Noninferiority of One HPV Vaccine Dose to Two Doses (NEJM) Herd effect of human papillomavirus vaccination on incidence of high-grade cervical lesions: (LANCET: Public Health) Confirmations of Highly Pathogenic Avian Influenza in Commercial and Backyard Flocks (USDA: Animal and Plant Health Inspection Service) Detections of Highly Pathogenic Avian Influenza in Wild Birds (USDA: Animal and Plant Health Inspection Service) Delaware, Georgia see major commercial avian flu outbreaks (CIDRAP) Wastewater for measles (WasterWater Scan) Notes from the Field: Wastewater Surveillance for Measles Virus During a Measles Outbreak — Colorado, August 2025 (CDC: MMWR) Notes from the Field: Retrospective Analysis of Wild-Type Measles Virus in Wastewater During a Measles Outbreak — Oregon, March 24–September 22, 2024 (CDC: MMWR) Measles cases and outbreaks (CDC Rubeola) Measles vaccine recommendations from NYP (jpg) Tracking Measles Cases in the U.S. (Johns Hopkins) Utah measles total rises to 216; CDC deputy director says losing elimination status'cost of doing business' (CIDRAP) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Assessing MMR vaccination coverage gaps in US children with digital participatory surveillance (Nature Health) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Effectiveness of influenza vaccination to prevent severe disease: a systematic review and meta-analysis of test-negative design studies (CMI: Clinical Microbiology and Infection) Interim vaccine effectiveness against influenza virus among outpatients, France, October 2025 to January 2026 (Eurosurveillance) Moderate protection from vaccination against influenza A(H3N2) subclade K in Beijing, China, September to December 2025 (Eurosurviellance) Current flu vaccine provides moderate protection against severe disease, interim analyses suggest (CIDRAP) OPTION 2: XOFLUZA $50 Cash Pay Option (xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virusnfection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) UnderstandingCoverageOptions (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1290 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Today's episode features Eileen Rivera Ley, a powerhouse at the intersection of business, innovation, and blindness advocacy. Eileen brings an impressive academic background, having earned a degree in economics from Harvard and an MBA from the Wharton School at the University of Pennsylvania. Her career includes work at the Wilmer Eye Institute at Johns Hopkins, but her entrepreneurial spirit ultimately led her to found Blind Savvy USA. Today, she serves as president of this innovative training and consulting company focused on low vision and blindness, helping organizations and individuals rethink what's possible through education, strategy, and lived experience.

The medical system expects you to chase 33 different screening appointments across multiple specialists and check your organs one at a time. But there's a smarter way that scans your entire body in under an hour to catch cancer, aneurysms, fatty liver, and other serious health issues before they become life-threatening. In today's episode, I sit down with Dr. Daniel Durand, Chief Medical Officer of Prenuvo, to talk about the real-world power (and limitations) of proactive whole-body MRI screening. Dr. Durand walks us through how this advanced screening method detects over 500 conditions, many of which traditional screenings miss. We talk about the importance of early detection for cancers and neurodegenerative diseases, and how this proactive approach to health can save lives.   "It's better to see things early when you can intervene, and see them in a controlled context when you're healthy." ~ Dr. Daniel Durand   In This Episode: -  Introduction to Dr. Daniel Durand and his background - Conventional vs whole body scans - Conditions that whole-body MRI can detect - Bringing scans to underserved populations - Imaging for risk identification vs. diagnosis - How often you should rescan and what to expect - EMF exposure concerns and MRI safety parameters - How consumer demand is driving change in medicine   Products & Resources Mentioned: Prenuvo Whole-Body MRI: My listeners get a special discount when you book at https://prenuvo.com/wendymyers  Bon Charge Blue Light Blockers: Get 15% off with code WENDY at https://boncharge.com  Organifi Happy Drops: Save 20% with code MYERSDETOX at https://organifi.com/myersdetox  Organifi Collagen: Use code MYERSDETOX for 20% off at https://organifi.com/myersdetox  Chef's Foundry P600 Ceramic Cookware: Get 20% off with code WENDY20 at https://chefsfoundry.com  Heavy Metals Quiz: Take it for free at https://heavymetalsquiz.com    About Dr. Daniel Durand: Dr. Daniel Durand is a dual board-certified adult & pediatric radiologist and Chief Medical Officer at Prenuvo, where he leads clinical operations, research, and the medical group for the world's largest network of proactive whole-body MRI clinics. Previously, he served as Chief Clinical Officer & Chief Innovation Officer at LifeBridge Health and held leadership roles in accountable care at Johns Hopkins. He is passionate about empowering primary care and shifting medicine toward true prevention through advanced imaging. Learn more at: https://prenuvo.com/wendymyers    Disclaimer The Myers Detox Podcast was created and hosted by Dr. Wendy Myers. This podcast is for information purposes only. Statements and views expressed on this podcast are not medical advice. This podcast, including Wendy Myers and the producers, disclaims responsibility for any possible adverse effects from using the information contained herein. The opinions of guests are their own, and this podcast does not endorse or accept responsibility for statements made by guests. This podcast does not make any representations or warranties about guests' qualifications or credibility. Individuals on this podcast may have a direct or indirect financial interest in products or services referred to herein. If you think you have a medical problem, consult a licensed physician.

Dr Bill Nelson speaks with Dr Gabriel Ivey, a gastrointestinal surgeon based in the National Capital Region, about his practice, the progress being made in patient outcomes, and the range of care options available at Johns Hopkins in the greater Washington DC area.

Well, it's time. Let's talk about President Dallin Harris Oaks, the Hoaks man, the Mormon Gollum. First, we cover the biography In the Hands of the Lord: The Life of Dallin H. Oaks by Richard Turley. Then we take a look at Hoaks' book The Carthage Conspiracy, as well as a presentation from 2021 where he actually uttered a prophecy! And after all that, we share some amazing science news. Researchers at Johns Hopkins have uncovered a surprising new way to influence brain activity by targeting a long-mysterious class of proteins linked to anxiety, schizophrenia, and movement disorders. Enjoy!   Show Notes:  Cyrus Dallin Sculptor: https://en.wikipedia.org/wiki/Cyrus_Edwin_Dallin  Cyrus Dallin: https://dallin.org/about-cyrus-dallin/  Stella Oaks Foundation: https://www.stellahoaks.org/    Law Review: https://en.wikipedia.org/wiki/Law_review  Supreme Court case 1957-1958: https://www.oyez.org/cases/1957  Chief Justice Earl Warren: https://www.oyez.org/justices/earl_warren  The Sit-In: 40 years later: https://chicagomaroon.com/22887/grey-city/the-sit-in-40-years-later/  Studying the Exclusionary Rule in Search and Seizure: https://nij.ojp.gov/library/publications/studying-exclusionary-rule-search-and-seizure  Why Dress and Grooming Standards: https://www.youtube.com/watch?v=56pD3WMPQao  Talk of the Month: Standards of Dress and Grooming: https://bhroberts.org/records/0spyAV-0Dx8uN/dallin_h_oaks_explains_byu_grooming_standards_in_the_new_era  Internal Revenue Service Investigations of Unidentified Persons, Denver Law Review: chrome-extension://oemmndcbldboiebfnladdacbdfmadadm/https://digitalcommons.du.edu/cgi/viewcontent.cgi?article=2923&context=dlr  United States vs Brigham Young University: https://law.justia.com/cases/federal/district-courts/FSupp/485/534/1377372/  The Wall Between Church and State: https://archive.org/details/wallbetweenchurc0000oaks/page/n5/mode/2up     MoGP: Carthage Conspiracy by Dallin Oaks and Marvin Hill https://www.press.uillinois.edu/books/?id=p007620 Dallin Oaks Lecture Nov 12, 2021 @ University of Virginia Mormon Studies https://www.youtube.com/watch?v=A0r2YIAsOQs   Happy News:  A "dormant" brain protein turns out to be a powerful switch: https://www.sciencedaily.com/releases/2026/01/260118233607.htm    Other appearances: Chris Shelton interviewed us in the beginning of a series on Mormonism on his Speaking of Cults series. Our most recent discussion was on the Mountain Meadows Massacre: https://youtu.be/iJWirjCyWdk  He has had MANY different fascinating people on so go take a look!  Here is the whole playlist: https://www.youtube.com/watch?v=OpGuS7GcsgA&list=PLGrPM1Pg2h72ADIuv8eYmzrJ-ppLOlw_g   Email: glassboxpodcast@gmail.com  Patreon: https://www.patreon.com/GlassBoxPod  Patreon page for documentary: https://www.patreon.com/SeerStonedProductions BlueSky: @glassboxpodcast.bsky.social  Other BlueSky: @bryceblankenagel.bsky.social and @shannongrover.bsky.social  Instagram: https://www.instagram.com/glassboxpodcast/  Merch store: https://www.redbubble.com/people/exmoapparel/shop Or find the merch store by clicking on "Store" here: https://glassboxpodcast.com/index.html One time Paypal donation: bryceblankenagel@gmail.com  Venmo: @Shannon-Grover-10  

In this episode of the Award-winning PRS Journal Club Podcast, 2026 Resident Ambassadors to the PRS Editorial Board – Lucas Harrison, Christopher Kalmar, and Priyanka Naidu- and special guest, Shai Rozen, MD, discuss the following articles from the January 2026 issue: "Extended Sural Nerve Harvest: A Technique to Gain Additional Graft Length" by Millesi, Gates-Tanzer, Felzen, et al. Read the article for FREE: https://bit.ly/SuralNerveExt Special guest, Shai Rozen is Professor and Vice-Chairman in the Department of Plastic Surgery at the University of Texas Southwestern Medical Center and Director of the Facial Reanimation Program, specializing in treating patients with facial paralysis. He completed both general surgery and plastic surgery training at Johns Hopkins, followed by fellowships in both craniofacial and peripheral nerve surgery.  READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCJan26Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

Summary In this episode, two university presidents, Dr. Sally Kornbluth (MIT) and Ron Daniels (Johns Hopkins) join Rob to talk about adult-onset Type 1 (LADA), leading in high-performance environments, and the single most “practical” diabetes upgrade: making a friend with diabetes. What stands out isn't prestige—it's how candidly they describe the everyday realities: managing highs and lows during major speeches, checking pumps in meetings, and staying open about diabetes to normalize it for everyone around them. The conversation also connects diabetes progress to the university research engine—past (insulin's discovery era) and future (stem cell/islet replacement, closed-loop algorithms, and emerging trials). Chapters * 00:26: Diagnosis stories through high-performance leadership lens + “patients first” approach * 01:02: Sally Kornbluth's adult-onset Type 1 (LADA) diagnosis * 02:55: Ron Daniels' adult-onset Type 1 diagnosis * 06:08: Adult-onset Type 1, LADA, and misdiagnosis risk * 08:29: Carbs, discipline, and the real lifestyle tradeoffs * 10:19: The biggest adjustment: mental load + fear of lows * 13:30: How they found each other + why “a friend with diabetes” changes everything * 21:41: Universities power diabetes progress (and what's next) * 42:45: Closing lessons: openness, resilience, and gratitude Resources Dr. Sally Kornbluth Ron Daniels

The offseason is HERE. But D1R does not sleep! We're joined by the Head Coach of Ottawa (KS) Nick Davis who led the Braves to a 6-5 record in 2025. We talk high school recruiting, culture and NAIA changing the game. Our Division 2 conversation revolves around the Harlon Hill winner Curtis Allen from Virginia Union and the Cliff Harris Award winner Justin Payoute from Ferris State, along with an interesting move from one of the top coaches in the country.In Division 3 we review some NCAA proposals that were denied/approved that could seriously alter the game, take a look at John Sullivan's incredible season at North Central, highlight an exciting new series between Johns Hopkins and Trinity (TX), and celebrate higher TV ratings for the Stagg Bowl!The NAIA conversation surrounds a contest with Northwestern scheduling FCS competition and Indiana Wesleyan signing a first-of-it's-kind media rights deal with Urban Edge Network. Thanks for tuning in!Video Chapters:0:00 Episode Overview3:34 Nick Davis - Ottawa Braves27:56 Curtis Allen's Harlon Hill Season33:23 Paul Simmons move to GM for Harding Football43:51 Justin Payoute - Cliff Harris Winner53:09 Trinity and Johns Hopkins New Series58:52 NCAA Proposals Changing the Game1:11:22 John Sullivan - Cliff Harris Winner1:17:38 Stagg Bowl Viewership Spike1:25:28 Northwestern schedules FCS Western IL1:34:25 Indiana Wesleyan's New Media Rights Deal

The American Cancer Society has updated guidelines for cervical cancer screening to include self-collected specimens to assess for human papilloma virus, or HPV. William Nelson, director of the Kimmel Cancer Center at Johns Hopkins, explains why. Nelson: There's 200,000 women … Will women soon be testing themselves for human papilloma virus, or HPV ? Elizabeth Tracey reports Read More »

For people who've had colorectal cancer, celecoxib, a commonly prescribed medicine for pain, may help avoid disease recurrence, a recent analysis of a larger study found. Kimmel Cancer Center director William Nelson at Johns Hopkins explains that the presence of … Can the drug celecoxib help some people avoid colorectal cancer recurrence? Elizabeth Tracey reports Read More »

In his weekly clinical update, Dr. Griffin and Vincent Racaniello are bewildered and dismayed by RFK Jr's announced changes in the routine childhood immunization schedule, though not unpredicted, and highlight the science and evidence which eviscerate these changes, then deep dives into recent statistics on the measles epidemic- in particular in South Carolina, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, estimated societal burden of COVID-19 illness, deaths and hospitalizations, benefit of maternal COVID-19 vaccination, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, neurodevelopmental consequences of in-utero SARS-CoV-2 infection and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode 7 great Danish cheeses you should know (Cheese Professor) Norovirus in on the rise! (WasterWater Scan) Maternal Vaccine Receipt and Infant Hospital and Emergency Visits for Influenza and Pertussis (JAMA Open) TUESDAY MEASLES UPDATE: DPH Reports 124 New Measles Cases in Upstate, New Public Exposures, and Upcoming Vaccination Opportunities (South Carolina: Department of Public Health-they have one?) Measles cases soar in South Carolina, top 400 (CIDRAP) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) USrespiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: cliff notes (CDC FluView) North Dakota confirms pediatric flu deaths as some states note surge in flu activity (CIDRAP) OPTION 2: XOFLUZA $50 Cash Pay Option (Xofluza) The Best Flu Drug Americans Aren't Taking (The Atlantic) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season(FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study (Lancet: Infectious Diseases) Interim Safety of RSVpreF Vaccination During Pregnancy (JAMA) Pfizer's RSV vaccine safe to use during pregnancy, study suggests (CIDRAP) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Evaluating the Effectiveness of 2024–2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Related Hospitalizations and Medically Attended COVID-19 Among Adults Aged ≥ 18 years in the United States: An Observational Matched Cohort Study (Infectious Diseases and Therapy) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) UnderstandingCoverageOptions (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis(Scientific Reports) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Incidence and Severity of Postacute Sequelae of SARS-CoV-2 Infection in the Omicron Era: A Prospective Cohort Study (JID) Reaching out to US house representative Letters read on TWiV 1288 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

NASA's SpaceX Crew-11 has returned to Earth, concluding a more than five-month mission aboard the International Space Station (ISS). Slingshot Aerospace has been awarded a $27 million US Space Force (USSF) contract to modernize scenario training activities. Chinese commercial company CAS Space debuted its suborbital two-stage research rocket, and more. Remember to leave us a 5-star rating and review in your favorite podcast app. Be sure to follow T-Minus on LinkedIn and Instagram. T-Minus Guest Our guest today is Cherie Matthew, Architect/ Project Manager at Jacobs.  You can connect with Cherie on LinkedIn, and learn more about Jacobs on their website. Selected Reading NASA's SpaceX Crew-11 Mission Returns, Splashes Down off California Slingshot Aerospace Awarded $27 Million Space Force Contract to Power the AI-Driven Training Environment for Space Warfare CAS Space Debuts Suborbital Research and Technology Testing Rocket Axelspace Signs MoU with Ethiopian Company to Address Social Challenges through the Utilization of Satellite Data Space Force Teams with Universities to Advance Sonic Boom Research in California NASA and Johns Hopkins play the cult video game DOOM on satellites Share your feedback. What do you think about T-Minus Space Daily? Please take a few minutes to share your thoughts with us by completing our brief listener survey. Thank you for helping us continue to improve our show.  Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at space@n2k.com to request more info. Want to join us for an interview? Please send your pitch to space-editor@n2k.com and include your name, affiliation, and topic proposal. T-Minus is a production of N2K Networks, your source for strategic workforce intelligence. © N2K Networks, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Don Watenpaugh is a scientist, sleep clinician, data artist, and poet with a PhD in physiology. His extensive career spans academia, NASA, and the U.S. Navy, focusing on human sleep, exercise, and environmental physiology. As a board-certified sleep medicine specialist, he directed a large urban sleep clinic for over 13 years, caring for patients and educating healthcare providers. Dr. Watenpaugh is an adjunct faculty member in physiology, anatomy, and biomedical engineering. He now creates data-driven art and poetry at Studio Videnda. In this episode, he brings his deep expertise to the critical relationship between sleep and concussion recovery.Episode Summary:In this episode of the Concussion Coach Podcast, host Bethany Lewis welcomes sleep expert Dr. Don Watenpaugh, to explore the complex connection between sleep disturbances and concussion recovery. Dr. Watenpaugh explains the physiological reasons why concussions commonly disrupt sleep—from brain inflammation impacting cerebral spinal fluid "brainwashing" during non-REM sleep to the exacerbation of pre-existing conditions like PTSD, depression, and anxiety. The conversation delves into the different types of insomnia (sleep onset and maintenance) and their potential causes, including restless leg syndrome and sleep apnea.Crucially, Dr. Watenpaugh provides actionable, evidence-based strategies to improve sleep and support brain healing. He discusses the evolving role of exercise as medicine, emphasizing safe, non-jarring activities like stationary cycling. He covers practical sleep hygiene tips, such as the importance of spinal alignment during sleep, the potential benefits of slightly elevating the head of the bed, and the disruptive effects of electronics and blue light. The discussion also touches on the careful use of supplements like melatonin, the special considerations for military personnel and student-athletes, and the overarching importance of patient education and self-advocacy. This episode is packed with science-backed insights to help listeners break the vicious cycle of poor sleep and prolonged concussion symptoms.Key Resources & Strategies Mentioned:Exercise as Medicine: Safe, mild-to-moderate exercise (e.g., stationary cycling to avoid head acceleration) can aid concussion recovery and improve sleep. Always consult your doctor.Sleep Position & Environment:Maintain spinal alignment; avoid stomach sleeping to prevent neck torsion.Consider slightly elevating the head of the bed to help reduce intracranial pressure.Remove electronics (TVs, phones) from the bedroom to avoid mental stimulation and blue light, which suppresses natural melatonin.Addressing Underlying Causes:Restless Leg Syndrome (RLS): Evening exercise (ending 2+ hours before bed) can help. Other treatments are available.Sleep Apnea: A common cause of sleep maintenance insomnia. Treatment (e.g., CPAP) is critical for overall health and concussion recovery.Hormonal Factors: Post-menopausal women may see a link between hormone changes and sleep apnea onset.Melatonin & Supplements: Prioritize natural melatonin production by managing light exposure. If using supplements, start with a low dose well before bedtime, monitor for side effects like headaches or grogginess, and consult your doctor.Patient Advocacy & Reliable Research: Dr. Watenpaugh stresses the importance of educating yourself using reliable, peer-reviewed sources like PubMed/MEDLINE, reputable medical institutions (e.g., Johns Hopkins & the Mayo Clinic), and professional organizations (e.g., American Academy of Sleep Medicine).Dr. Don Watenpaugh's website:Website/Data Art Studio: https://www.studiovidenda.comBethany Lewis & The Concussion Coach:Free Guide: "5 Best Ways to Support Your Loved One Dealing with a Concussion" - Download at www.theconcussioncoach.comConcussion Coaching Program: For personalized mentorship in recovery. Sign up for a free consultation HERE

In this episode of the Award-winning PRS Journal Club Podcast, 2026 Resident Ambassadors to the PRS Editorial Board – Lucas Harrison, Christopher Kalmar, and Priyanka Naidu- and special guest, Shai Rozen, MD, discuss the following articles from the January 2026 issue: "The Natural Progression of Synkinesis" by Rail, Bhatia, Dragun, et al. Read the article for FREE: https://bit.ly/NaturalSynk Special guest, Shai Rozen is Professor and Vice-Chairman in the Department of Plastic Surgery at the University of Texas Southwestern Medical Center and Director of the Facial Reanimation Program, specializing in treating patients with facial paralysis. He completed both general surgery and plastic surgery training at Johns Hopkins, followed by fellowships in both craniofacial and peripheral nerve surgery.  READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCJan26Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

Protests are sweeping Iran and the government is cracking down hard, fearing the uprisings pose a threat to the theocratic regime. There is an internet blackout in the country making it hard to get information. We hear a rare first-person account of the protests from a Johns Hopkins professor who visits the Iran frequently and who recently attended a protest there.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

We kicked off the program with four news stories and different guests on the stories we think you need to know about! THE POWER OF THE PAUSE: 90 Seconds to Calm, Reset, and Reconnect.Guest: Jillian Pransky – Author & mindfulness teacher & Yoga therapist 5 Ways to Use AI for a Healthier 2026. Accessible AI tools and affordable wearables can simplify healthy habits rather than overwhelm people. New Book: Better Health with AI: Simple Steps to Real ResultsGuest: Dr. Earl J. Campazzi, Jr, a Johns Hopkins–trained preventive medicine physician with 35+ years of clinical experience and four board certifications Why you should put down your phone and daydream insteadGuest: Maggie Penman – WaPo Reporter In reversal, U.S. loosens guidance on alcoholGuest: David Ovalle – WaPo Reporter that focuses on opioids and addiction See omnystudio.com/listener for privacy information.

Luke Hedrick, Dave Furfaro, and recurrent RFJC guest Robert Wharton are joined again today by Nicole Ng to discuss the FIBRONEER-IPF trial investigating Nerandomilast in patients with IPF. This trial was published in NEJM in 2025 and looked at Neradomilast vs placebo for treating patients with IPF, on or off background anti-fibrotic therapy. This agents is now FDA approved for pulmonary fibrosis, and understanding the trial results is essential for any pulmonary physician treating patients with IPF or progressive pulmonary fibrosis. Article and Reference Today’s episode discusses the FIBRONEER-IPF trial published in NEJM in 2025. Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Clerisme-Beaty E, Gordat M, Wachtlin D, Liu Y, Schlecker C, Stowasser S, Zoz DF, Wijsenbeek MS; FIBRONEER-IPF Trial Investigators. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12;392(22):2193-2202. doi: 10.1056/NEJMoa2414108. Epub 2025 May 18. PMID: 40387033. https://www.nejm.org/doi/abs/10.1056/NEJMoa2414108 Meet Our Guests Luke Hedrick is an Associate Editor at Pulm PEEPs and runs the Rapid Fire Journal Club Series. He is a senior PCCM fellow at Emory, and will be starting as a pulmonary attending at Duke University next year. Robert Wharton is a recurring guest on Pulm PEEPs as a part of our Rapid Fire Journal Club Series. He completed his internal medicine residency at Mt. Sinai in New York City, and is currently a pulmonary and critical care fellow at Johns Hopkins. Dr. Nicole Ng is an Assistant Profess of Medicine at Mount Sinai Hospital, and is the Associate Director of the Interstitial Lung Disease Program for the Mount Sinai National Jewish Health Respiratory Institute. Infographic Key Learning Points Why this trial mattered IPF therapies remain limited: nintedanib and pirfenidone slow (but do not stop) decline and often cause GI side effects. Nerandomilast is a newer agent (a preferential PDE4B inhibitor) with antifibrotic + immunomodulatory effects. Phase 2 data (NEJM 2022) looked very promising (suggesting near-“halt” of FVC decline), so this phase 3 trial was a big test of that signal. Trial design essentials Industry-sponsored, randomized, double-blind, placebo-controlled, large multinational study (332 sites, 36 countries). Population: IPF diagnosed via guideline-aligned criteria with central imaging review and multidisciplinary diagnostic confirmation. Intervention: nerandomilast 18 mg BID, 9 mg BID, or placebo; stratified by background antifibrotic use. Primary endpoint: change in FVC at 52 weeks, analyzed with a mixed model for repeated measures. Key secondary endpoint: time to first acute exacerbation, respiratory hospitalization, or death (composite). Who was enrolled Typical IPF trial demographics: ~80% male, mean age ~70, many former smokers. Many were already on background therapy (~45% nintedanib, ~30–33% pirfenidone). Notable exclusions included significant liver disease, advanced CKD, recent major cardiovascular events, and psychiatric risk (suicidality/severe depression), reflecting class concerns seen with other PDE4 inhibitors. Efficacy: what the primary endpoint showed Nerandomilast produced a statistically significant but modest reduction in annual FVC decline vs placebo (roughly 60–70 mL difference). Importantly, it did not halt FVC decline the way the phase 2 data suggested; patients still progressed. Important nuance: interaction with pirfenidone Patients on pirfenidone had ~50% lower nerandomilast trough levels. Clinically: 9 mg BID looked ineffective with pirfenidone, so 18 mg BID is needed if used together. In those not on background therapy or on nintedanib, 9 mg and 18 mg looked similar—suggesting the apparent “dose-response” might be partly driven by the pirfenidone drug interaction Secondary and patient-centered outcomes were neutral No demonstrated benefit in the composite outcome (exacerbation/resp hospitalization/death) or its components. Quality of life measures were neutral and declined in all groups, emphasizing that slowing FVC alone may not translate into felt improvement without a disease-reversing therapy. The discussants noted this may reflect limited power/duration for these outcomes and mentioned signals from other datasets/pooling that might suggest mortality benefit—but in this specific trial, the key secondary endpoint was not positive. Safety and tolerability Diarrhea was the main adverse event: Higher overall with the 18 mg dose, and highest when combined with nintedanib (up to ~62%). Mostly mild/manageable; discontinuation due to diarrhea was relatively uncommon (but higher in those on nintedanib). Reassuringly, there was no signal for increased depression/suicidality/vasculitis despite psychiatric exclusions and theoretical class risk. How to interpret “modest FVC benefit” clinically The group framed nerandomilast as another tool that adds incremental slowing of progression. They emphasized that comparing absolute FVC differences across trials (ASCEND/INPULSIS vs this trial) is tricky because populations and “natural history” in placebo arms have changed over time (earlier diagnosis, improved supportive care, etc.). They highlighted channeling bias: patients already on antifibrotics may be sicker (longer disease duration, lower PFTs, more oxygen), complicating subgroup comparisons. Practical takeaways for real-world use All three antifibrotics are “fair game”; choice should be shared decision-making based on goals, tolerability, dosing preferences, and logistics. Reasons they favored nerandomilast in practice: No routine lab monitoring (major convenience advantage vs traditional antifibrotics). Generally better GI tolerability than nintedanib. BID dosing (vs pirfenidone TID). Approach to combination therapy: They generally favor add-on rather than immediate combination to reduce confusion about side effects—while acknowledging it may slow reaching “maximal therapy.” Dosing guidance emphasized: Start 18 mg BID for IPF, especially if combined with pirfenidone (since dose reduction may make it ineffective). 9 mg BID may be considered if dose reduction is needed and the patient is not on pirfenidone (e.g., monotherapy or with nintedanib).

414 Following Your Own Star   There comes a time in our lives where we need to stop and take stock of what we want to do next and our next steps in getting there. Perhaps it's more than just one thing, perhaps you're just floating through life trying to figure out what to do next, or perhaps you think this goal is too lofty despite all your hard work. Which is why it is so important to take all you know about others and yourself and apply it to whatever comes next. In today's episode Sarah Elkins and Professor KD Frick discuss the importance of that specific personal growth, as well as the importance of believing in others and yourself even when you aren't sure where your own star is leading you, and especially to greet the world with open arms.   Highlights Finding the right words for where you are in your life right now.  Leading with compassion and empathy. Position yourself to be able to understand.  Don't immediately dismiss someone, you never know where their combined ideas may lead. Everyone has their own North Star they follow.   Quotes "Empathy leads to approachability." "Look as long as I'm here and unless you tell me otherwise, I'm planning on reading names. Because it's the last connection students have with us."    Dear Listeners it is now your turn, What did you hear in this conversation that struck you as something that resonated? Maybe it was about not knowing what you want to do next, maybe it was I do know what I want to do next but I'm not being consistent enough to make it happen. I am so curious to hear your thoughts, please share them either in the comments or wherever you see this shared or send me an email.  And, as always, thank you for listening.    About KD KD Frick was originally trained as a health economist and began a career at Johns Hopkins as a faculty member at the Bloomberg School of Public Health; after a bit more than sixteen years in that role, with responsibilities like associate department chair and faculty senate president, a move was made to the Carey Business School as vice dean for education. The eight and one-half years spent in that role were a time of growth and expansion of opportunity. With colleagues encouraging a return to research, challenging decisions around COVID, a focus on ranking academic programs that was not of interest, and a lack of visible opportunities for advancement in administration, a decision was made to return to just a faculty role. The result has been great fulfillment, a change in teaching, and a focus on leading by teaching others to lead artisnally toward aspirational narratives for themselves and those they are developing. There is still room for work on the economics of eye care where Professor Frick has the opportunity to apply the leading with values approach that is taught in the classroom. Be sure to check out Professor Frick's LinkedIn, thoughts on tHERSday newsletter, as well as Business and Economics of Eye Care and Health!   About Sarah "Uncovering the right stories for the right audiences so executives, leaders, public speakers, and job seekers can clearly and actively demonstrate their character, values, and vision." In my work with coaching clients, I guide people to improve their communication using storytelling as the foundation of our work together. What I've realized over years of coaching and podcasting is that the majority of people don't realize the impact of the stories they share - on their internal messages, and on the people they're sharing them with. My work with leaders and people who aspire to be leaders follows a similar path to the interviews on my podcast, uncovering pivotal moments in their lives and learning how to share them to connect more authentically with others, to make their presentations and speaking more engaging, to reveal patterns that have kept them stuck or moved them forward, and to improve their relationships at work and at home. The audiobook, Your Stories Don't Define You, How You Tell Them Will is now available! Included with your purchase are two bonus tracks, songs recorded by Sarah's band, Spare Change, in her living room in Montana. Be sure to check out the Storytelling For Professionals Course as well to make sure you nail that next interview!

Dr. James Greenblatt, MD, is more than a dual board-certified psychiatrist; he is a pioneer of hope and a tireless advocate for the integration of soul and science. For over 30 years, Dr. Greenblatt has looked beyond the traditional "checklist" of symptoms to uncover the vibrant, biochemical story beneath. As the leading global expert on the clinical application of low-dose lithium and a pioneer in functional psychiatry, he has dedicated his career to a singular, transformative mission: healing the root cause so the spirit can flourish. From his academic roots at Johns Hopkins and George Washington University to his current faculty roles at Tufts and Dartmouth, Dr. Greenblatt bridges the gap between clinical excellence and compassionate, precision-based care. Through his educational platform, Psychiatry Redefined, he is shifting the global landscape of mental health—empowering a new generation of clinicians to treat the whole person rather than just the diagnosis. A prolific voice in the holistic movement, Dr. Greenblatt has authored nine life-changing books, including the bestsellers Finally Focused and Nutritional Lithium. His work invites us to reimagine what is possible for our mental well-being, moving away from temporary fixes toward a state of true, sustainable inner balance. Whether through his writing or his upcoming 2026 release, Finally Hopeful, Dr. Greenblatt continues to light the path for those seeking to reclaim their health, their clarity, and their lives.

Mifepristone used with misoprostol is the most common abortion regimen in the US. It is also a focal point of reproductive health policy and politics, with controversy over its legal status and regulation by the US Food and Drug Administration (FDA). Author G. Caleb Alexander, MD, MS, from Johns Hopkins discusses this and more with JAMA Deputy Editor Joseph S. Ross, MD, MHS. Related Content: The US Food and Drug Administration's Regulation of Mifepristone Politics, Science, and the Future of FDA Drug Regulation

This week, Tee sits down with Dr. Beverly Jensen for a powerful conversation on the often-overlooked impact of electromagnetic fields (EMFs) on our health, homes, and especially our children. Dr. Beverly brings a rare blend of academic rigor, international experience, and lived wisdom. Her early career included writing on health, nutrition, and environmental education for Woman's Day, Teacher, and McGraw-Hill. She later earned her doctorate in international communication from the University of Washington and went on to build a global career spanning Egypt, the Czech Republic, and the UAE. From launching a nationally adopted noise-abatement campaign in Egypt to managing a World Bank–backed Heart Association project in the Czech Republic, Dr. Jensen has spent decades at the intersection of public health, communication, and advocacy. She also co-managed a Johns Hopkins–affiliated health promotion program in the UAE, helping shape initiatives later adopted by the Abu Dhabi Health Authority. In this episode, Tee and Dr. Jensen explore how everyday EMF exposure from cell phones to household appliances can affect daily life and childhood development. Dr. Jensen shares her personal journey into EMF awareness, practical steps families can take to reduce exposure, and why public education and legislative involvement are urgently needed. The conversation also highlights the vital role mothers play in advocating for children's long-term health. Connect with Dr.Beverly: You and EMF  Women's Medicine Bowl  Free Consultation LinkedIn Facebook YouTube Contact Your Representative Regarding House Bill 2289 National Call For Safe Technology Follow Therese "Tee" Forton-Barnes and The Green Living Gurus: Austin Air Purifiers: For podcast listeners, take 15% off any Austin Air product; please email Tee@thegreenlivinggurus.com and mention that you want to buy a product and would like the discount. See all products here: Austin Air The Green Living Gurus' Website  Instagram YouTube Facebook Healthy Living Group on Facebook Tip the podcaster! Support Tee and the endless information that she provides: Patreon Venmo: @Therese-Forton-Barnes last four digits of her cell are 8868 For further info, contact Tee: Email: Tee@thegreenlivinggurus.com Cell: 716-868-8868 DISCLAIMER: ALL INFORMATION PROVIDED HERE IS GENERAL GUIDANCE AND NOT MEANT TO BE USED FOR INDIVIDUAL TREATMENT. PLEASE CONTACT YOUR PROVIDER OR DOCTOR FOR MEDICAL ADVICE.   Produced By: Social Chameleon

In his weekly clinical update, Dr. Griffin and Vincent Racaniello are bewildered and dismayed by RFK Jr's announced changes in the routine childhood immunization schedule, though not unpredicted, and highlight the science and evidence which eviscerate these changes, then deep dives into recent statistics on the measles epidemic- in particular in South Carolina, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, estimated societal burden of COVID-19 illness, deaths and hospitalizations, benefit of maternal COVID-19 vaccination, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, neurodevelopmental consequences of in-utero SARS-CoV-2 infection and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Childhood Immunization Schedule by Recommendation Group (US Health and Human Service) Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger (American Academy of Pediatrics) Kennedy Scales Back the Number of Vaccines Recommended for Children (NY Times) There RFK Jr. Goes Again . . .(Wall Street Journal) Hepatitis B Vaccination is an Essential Safety Net for Newborns (Johns Hopkins Bloomberg School of Public Health) Effectiveness and Impact of Maternal RSV Immunization and Nirsevimab on Medically Attended RSV in US Children (JAMA Pediatrics) Rotavirus (College of Physicians of Philadelphia) Hepatitis A in the Era of Vaccination (Epidemiologic Reviews) Meningococcal Vaccination in the United States: Past, Present, And Future (Ped Drugs) Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020 (CDC: MMWR) N.Y. DOH says childhood vaccine recommendations remain unchanged despite CDC's update (Spectrum 1 News) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) South Carolina measles cases rise by 26 to 211, state health department says (Reuters) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: cliff notes (CDC FluView) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) Estimated Burden of COVID-19 Illnesses, Medical Visits, Hospitalizations, and Deaths in the US From October 2022 to September 2024 (JAMA Internal Medicine) The Role of Vaccination in Maternal and Perinatal Outcomes Associated With COVID-19 in Pregnancy (JAMA) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) UnderstandingCoverageOptions (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID The COVID generation: the neurodevelopmental consequences of in-utero COVID-19 exposure (Brain, behavior and Immunity) Reaching out to US house representative Letters read on TWiV 1286 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

In this episode of the Award-winning PRS Journal Club Podcast, 2026 Resident Ambassadors to the PRS Editorial Board – Lucas Harrison, Christopher Kalmar, and Priyanka Naidu- and special guest, Shai Rozen, MD, discuss the following articles from the January 2026 issue: "The Efficacy of Flap Debulking after Facial Reanimation Surgery to Enhance Facial Symmetry" by Weiss, Fricke, Hohenstein, et al. Read the article for FREE: https://bit.ly/FlapDebulk Special guest, Shai Rozen is Professor and Vice-Chairman in the Department of Plastic Surgery at the University of Texas Southwestern Medical Center and Director of the Facial Reanimation Program, specializing in treating patients with facial paralysis. He completed both general surgery and plastic surgery training at Johns Hopkins, followed by fellowships in both craniofacial and peripheral nerve surgery.  READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCJan26Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

Recording after the ball drops, Dr. Griffin and Vincent Racaniello wish everyone a Happy New Year, discuss an evidence-based approach to teaching and practice medicine and reminisce on the history of vaccine development and use before their discussion about the whooping cough outbreak of 2025 in the US and falling levels of tetanus vaccination, then Dr. Griffin then deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, how NY state reported the greatest number of influenza confirmed infections ever in one week during the week ending Dec 20,  where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Evidence-Based Medicine: A New Approach to Teaching the Practice of Medicine (JAMA) The US has seen nearly 28,000 whooping cough cases this year. Here's what you need to know (CNN) Vaccine History: Developments by Year (CHOP, Children's hospital of Philadelphia: Vaccine History) Reported Incidence of notable diseases in United States: 1952 Morbidity and Mortality Weekly Report, Vol. 1, No. 54, October 26, 1953 (CDC: Stacks) As tetanus vaccination rates decline, doctors worry about rising case numbers (nbc News) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) New York State Department of Health Confirms Most Flu Cases Ever Recorded in One Week: New York State Reports 71,123 Flu Cases This Week (NY State Department of Health) Weekly surveillance report: cliff notes (CDC FluView) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus–Related Hospitalization in Newborns (JAMA) RSV Immunization Frequently Asked Questions(American Academy of Pediatrics) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) UnderstandingCoverageOptions (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1284 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.